ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

摘要:

A combination of tretinoin [retinoic acid] and indomethacin may become the first effective therapy for patients with myelodysplasia, a condition that can progress to leukaemia. The drug combination is currently in phase II trials in the UK. It is hoped that the treatment will offer a real alternative to blood transfusions by overcoming the problems of neutrophil deficiency for patients with this preleukaemic condition. The potential of this new form of therapy was described as‘very exciting’by a spokesman from the UK Leukaemia Research Fund.Inpharmafound out more about the project by speaking to one of the lead researchers, Dr Geoff Brown from the University of Birmingham, UK.

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

摘要:

The economic burden of cancer in the US is immense, costing society an estimated $US104 billion/year. Notably, a significant proportion of this total cost is attributable to chemotherapy-induced toxicities. At one session held at the American Society of Health-System Pharmacists Annual Meeting [Minneapolis, US; June 1997],#researchers discussed the costs associated with chemotherapy-induced toxicities, as well as cost-effective strategies for the management of such toxicities. They believe that the chemoprotectant amifostine is effective in the management of chemotherapy-induced toxicities, but that its high acquisition cost requires that pharmacoeconomic analyses be conducted. The results of cost analyses place amifostine in a favourable light.

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS